Lymphatic Diseases
22
2
8
11
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
4.5%
1 terminated out of 22 trials
91.7%
+5.1% vs benchmark
9%
2 trials in Phase 3/4
55%
6 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (22)
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma
A Prospective Natural History Study of Lymphatic Anomalies
Prevalence of Chapman Reflex Points in Medical Students and Their Association With Visceral Symptoms
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
Lymphatic Phenotype in Noonan Syndrome Spectrum Disorders
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma
Lymphaticovenous Anastomosis as Treatment for Lymphedema
A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Octreotide Improves Human Lymphatic Fluid Transport a Translational Trial
Sildenafil for the Treatment of Lymphatic Malformations
Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients
Micro-mobile Foot Compression and Diabetic Foot
Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting
"Effects of Manual Lymphatic Drainage in the Neck in Healthy Subjects. Experimental Randomized Crossover Study"
Effectiveness of Intracavitary Manual Lymphatic Drainage